Thyroid hormone therapy in dogs
Pro Research Analysisby 
Searched over 200M research papers
Thyroid Hormone Replacement Therapy in Canine Hypothyroidism
Thyroid hormone therapy, particularly with levothyroxine (L-thyroxine), is the standard treatment for dogs diagnosed with hypothyroidism. Clinical and laboratory improvements are typically achieved with a mean dose of 0.026 mg/kg once daily, though some dogs may require dose adjustments to reach optimal control. Lethargy and mental dullness are often the first symptoms to improve, and significant weight reduction can be seen within two weeks of starting therapy. While routine blood tests help confirm a general metabolic response, they are less useful for fine-tuning individual therapy. Measurement of canine thyroid-stimulating hormone (cTSH) can indicate inadequate therapy if elevated, but normal cTSH values do not always guarantee adequate treatment, limiting its usefulness for ongoing monitoring .
Behavioral and Neurohormonal Effects of Levothyroxine in Dogs
Levothyroxine supplementation in hypothyroid dogs has been shown to increase activity levels after six weeks of treatment. However, no significant changes in aggression, other behavioral signs, or neurohormonal markers such as serotonin and prolactin were observed after six months of therapy. This suggests that while thyroid hormone therapy can improve lethargy and general activity, it may not have a substantial impact on other behavioral or neurohormonal parameters in the long term .
Gastrointestinal Signs and Thyroid Hormone Therapy
Gastrointestinal (GI) symptoms, including constipation and diarrhea, are common in hypothyroid dogs, affecting about 45% of cases. Thyroid hormone replacement therapy leads to significant improvement in these GI signs, supporting a strong association between hypothyroidism and GI disturbances in dogs. Additionally, hypothyroid dogs are more likely to have gallbladder abnormalities, which may also improve with therapy .
Effects on Erythropoiesis and Blood Parameters
Thyroid hormones influence red blood cell production in dogs. After two months of levothyroxine therapy, positive correlations were observed between T4 levels and red blood cell indices, such as hemoglobin content, while a negative correlation was seen with hematocrit. This highlights the role of thyroid hormones in supporting normal erythropoiesis, although classic anemia associated with hypothyroidism was not consistently observed .
Adverse Reactions to Thyroid Hormone Supplements
While rare, dogs can experience hypersensitivity reactions to inactive ingredients in thyroid hormone supplements, such as magnesium stearate and polyvinylpyrrolidone. Switching to a formulation without these ingredients resolved the reaction, emphasizing the importance of considering excipients in cases of suspected drug allergy .
Thyroid Hormone Therapy in Dogs with Thyroid Carcinoma
Radioactive iodine (I-131) therapy is an effective treatment for dogs with thyroid carcinoma, leading to prolonged survival even in advanced cases. The addition of recombinant human thyroid-stimulating hormone (rhTSH) can further increase radioactive iodine uptake by tumors, potentially improving treatment efficacy. Most dogs tolerate I-131 therapy well, and hyperthyroidism, when present, typically resolves after treatment Scheemaeker2024Cowan2023.
Interactions with Other Treatments and Hormones
In dogs with pituitary-dependent hyperadrenocorticism, treatment with trilostane can increase cTSH concentrations, reflecting changes in the hypothalamic-pituitary-thyroid axis. However, significant changes in thyroxine levels are not consistently observed. This interaction highlights the complexity of managing concurrent endocrine disorders in dogs .
Administration of melatonin in dogs, both castrated and intact, can decrease T3 and T4 concentrations, as well as other metabolic hormones. This suggests that melatonin may influence thyroid hormone levels and should be considered when evaluating thyroid function in treated dogs .
Conclusion
Thyroid hormone therapy, primarily with levothyroxine, is effective in managing canine hypothyroidism, improving clinical signs such as lethargy, weight gain, and gastrointestinal disturbances. Dose adjustments are often necessary, and while routine monitoring is helpful, some laboratory markers have limitations. Adverse reactions to inactive ingredients are rare but possible. In cases of thyroid carcinoma, radioactive iodine therapy, especially when combined with rhTSH, offers promising outcomes. Awareness of drug interactions and the effects of other hormones, such as melatonin, is important for comprehensive management.
Sources and full results
Most relevant research papers on this topic